The assessment of the clinical progression of the postoperative period in patients with neuroepithelial brain tumors when using intraoperative local chemotherapy (iLCT) with Temodex, which is an anticancer medicinal product of the active substance of temozolomide immobilized on highly substituted dextran phosphate. Clinical manifestations and features of the early postoperative period were analyzed depending on the radicality of tumor resection, its localization and extension. Complications and causes of mortality were studied in patients undergoing standard surgery and iCLT. It was shown that the frequency and nature of complications when using Temodex did not differ from those in the control group.
Authors: M D.P. Veevnik, A.S. Fedulov, A.A. Borovsky, A.V. Shamkalovich, T.L. Yurkshtovich, T.L. Yurkshtovich
Keywords: primary neuroepithelial brain tumors, intraoperative local chemotherapy, temozolomide, temodeks, security, tolerability.
Contact information
Full Company Name:
Double Bond Pharmaceutical International AB (publ)
Corporate identity:
556991-6082
Stock short name:
DBP B
Share ISIN code:
SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage:
E-mail:
Blog:
Follow us on:
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.